NovaBay Pharmaceuticals (NYSE:NBY) Earns Hold Rating from Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a report released on Monday. The brokerage set a “hold” rating on the stock.

NovaBay Pharmaceuticals Stock Performance

NYSE NBY opened at $0.63 on Monday. NovaBay Pharmaceuticals has a one year low of $0.36 and a one year high of $9.08. The firm has a market cap of $3.33 million, a PE ratio of -0.01 and a beta of 0.73. The firm’s fifty day moving average is $0.66 and its two-hundred day moving average is $0.63.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.